Tiludronic acid
Bisphosphonate — MUSCULO-SKELETAL SYSTEM
Also known as: tiludronate, tiludronate disodium
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Tiludronic acid is an ofm drug in the Bisphosphonate class catalogued in DrugCentral. It was first approved by the FDA in 1997. DrugCentral lists 6 molecular targets, including MMP2, MMP14 and MMP8. Recorded indications include Osteitis deformans.
- Approval status: ofm (first approved 1997 by the FDA).
- Drug class: Bisphosphonate.
- Molecular targets: MMP2, MMP14, MMP8 and MMP1 (6 listed in DrugCentral).
- Indications: Osteitis deformans.
- ATC code: M05BA05 (Bisphosphonates).
- Molecular formula: C7H9ClO6P2S; molecular weight 318.60 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Osteitis deformans
Contraindications (21)
- Acute nephropathy
- Anemia
- Aseptic necrosis of bone of jaw
- Bed-ridden
- Blood coagulation disorder
- Duodenitis
- Dysphagia
- Esophageal dysmotility
- Esophageal Obstruction
- Fracture of femur
- Gastritis
- Hyperparathyroidism
- Hyperphosphatemia
- Hypocalcemia
- Invasive Dental Procedure
- Kidney disease
- Peptic ulcer
- Periodontitis
- Primary malignant neoplasm
- Stricture of esophagus
- Vitamin D deficiency
Mechanism & targets
| Established pharmacologic class | Bisphosphonate |
|---|
Molecular targets (6)
| Target | Gene | Action | Activity |
|---|---|---|---|
| 72 kDa type IV collagenase | MMP2 | unknown | IC50 5.14 |
| Matrix metalloproteinase-14 | MMP14 | unknown | IC50 4.52 |
| Neutrophil collagenase | MMP8 | unknown | IC50 4.49 |
| Interstitial collagenase | MMP1 | unknown | IC50 4.30 |
| Tyrosine-protein phosphatase non-receptor type 1 | PTPN1 | unknown | — |
| V-type proton ATPase 116 kDa subunit a isoform 3 | TCIRG1 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1997-03-07 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
M05BA05 | MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Bisphosphonates |
Chemical structure
| Molecular formula | C7H9ClO6P2S |
|---|---|
| Molecular weight | 318.60 g/mol |
| CAS number | 89987-06-4 |
| InChIKey | DKJJVAGXPKPDRL-UHFFFAOYSA-N |
| PubChem CID | 60937 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Tiludronic acid used for?
DrugCentral lists the following indications for Tiludronic acid: Osteitis deformans.
How does Tiludronic acid work?
Its molecular targets in DrugCentral include MMP2, MMP14, MMP8 and MMP1.
When was Tiludronic acid first approved?
Tiludronic acid was first approved by the FDA in 1997.
What drug class does Tiludronic acid belong to?
Tiludronic acid is in the Bisphosphonate class.
What is the chemical formula of Tiludronic acid?
Tiludronic acid has the molecular formula C7H9ClO6P2S and a molecular weight of 318.60 g/mol.
Browse: all drugs starting with T · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2666 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200448 — compound record and bioactivity
- PubChem CID 60937 — chemical identifiers
- DrugBank DB01133 — drug record
- FDA UNII 6PNS59HP4Y — substance identity
- DailyMed: FDA labels for Tiludronic acid — current prescribing information (label search)
- UniProt P08253 (MMP2) — target protein
- UniProt P50281 (MMP14) — target protein
- UniProt P22894 (MMP8) — target protein
- UniProt P03956 (MMP1) — target protein
- UniProt P18031 (PTPN1) — target protein
- UniProt Q13488 (TCIRG1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.